Market Cap : 4.1 B | Enterprise Value : 4.85 B | PE Ratio : At Loss | PB Ratio : 1.79 |
---|
TDOC has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
TDOC has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
The zones of discrimination were as such:
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Teladoc Health has an F-score of 4 indicating the company's financial situation is typical for a stable company.
The historical rank and industry rank for Teladoc Health's Piotroski F-Score or its related term are showing as below:
During the past 10 years, the highest Piotroski F-Score of Teladoc Health was 6. The lowest was 2. And the median was 4.
The historical data trend for Teladoc Health's Piotroski F-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, Teladoc Health's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Healthcare Providers & Services industry and Healthcare sector, Teladoc Health's Piotroski F-Score distribution charts can be found below:
* The bar in red indicates where Teladoc Health's Piotroski F-Score falls in comparison to its industry or sector. The grey bar indicates the Piotroski F-Score's extreme value range as defined by GuruFocus.
How is the Piotroski F-Score calculated?
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
This Year (Mar23) TTM: | Last Year (Mar22) TTM: |
Net Income was -3101.461 + -73.476 + -3810.071 + -69.228 = $-7,054 Mil. Cash Flow from Operations was 92.469 + 63.021 + 65.549 + 13.156 = $234 Mil. Revenue was 592.379 + 611.402 + 637.709 + 629.244 = $2,471 Mil. Gross Profit was 409.909 + 425.783 + 448.836 + 439.137 = $1,724 Mil. Average Total Assets from the begining of this year (Mar22) to the end of this year (Mar23) was (11092.337 + 8102.775 + 8103.965 + 4345.355 + 4309.147) / 5 = $7190.7158 Mil. Total Assets at the begining of this year (Mar22) was $11,092 Mil. Long-Term Debt & Capital Lease Obligation was $1,572 Mil. Total Current Assets was $1,287 Mil. Total Current Liabilities was $381 Mil. |
Net Income was -133.819 + -84.34 + -10.985 + -6674.523 = $-6,904 Mil. Revenue was 503.139 + 521.658 + 554.235 + 565.35 = $2,144 Mil. Gross Profit was 342.866 + 352.617 + 379.25 + 378.325 = $1,453 Mil. Average Total Assets from the begining of last year (Mar21) to the end of last year (Mar22) was (17582.358 + 17611.119 + 17652.579 + 17734.608 + 11092.337) / 5 = $16334.6002 Mil. Total Assets at the begining of last year (Mar21) was $17,582 Mil. Long-Term Debt & Capital Lease Obligation was $1,573 Mil. Total Current Assets was $1,208 Mil. Total Current Liabilities was $307 Mil. |
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Teladoc Health's current Net Income (TTM) was -7,054.
==> Negative ==> Score 0.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Teladoc Health's current Cash Flow from Operations (TTM) was 234.
==> Positive ==> Score 1.
Question 3. Change in Return on Assets
Compare this year's return on assets (1) to last year's return on assets.
Score 1 if it's higher, 0 if it's lower.
ROA (This Year) | = | Net Income | / | Total Assets (Mar22) |
= | -7054.236 | / | 11092.337 | |
= | -0.6359558 |
ROA (Last Year) | = | Net Income | / | Total Assets (Mar21) |
= | -6903.667 | / | 17582.358 | |
= | -0.39264739 |
Teladoc Health's return on assets of this year was -0.6359558. Teladoc Health's return on assets of last year was -0.39264739.
==> Last year is higher ==> Score 0.
Question 4. Quality of Earnings (Accrual)
Compare Cash flow return on assets (2) to return on assets (1)
Score 1 if CFROA > ROA, 0 if CFROA <= ROA.
Teladoc Health's current Net Income (TTM) was -7,054. Teladoc Health's current Cash Flow from Operations (TTM) was 234.
==> 234 > -7,054 ==> CFROA > ROA ==> Score 1.
Funding
Question 5. Change in Gearing or Leverage
Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.
Score 0 if this year's gearing is higher, 1 otherwise.
Gearing (This Year: Mar23) | = | Long-Term Debt & Capital Lease Obligation | / | Average Total Assets from Mar22 to Mar23 |
= | 1572.061 | / | 7190.7158 | |
= | 0.21862371 |
Gearing (Last Year: Mar22) | = | Long-Term Debt & Capital Lease Obligation | / | Average Total Assets from Mar21 to Mar22 |
= | 1572.943 | / | 16334.6002 | |
= | 0.09629516 |
Teladoc Health's gearing of this year was 0.21862371. Teladoc Health's gearing of last year was 0.09629516.
==> Last year is lower than this year ==> Score 0.
Question 6. Change in Working Capital (Liquidity)
Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.
Score 1 if this year's current ratio is higher, 0 if it's lower
Current Ratio (This Year: Mar23) | = | Total Current Assets | / | Total Current Liabilities |
= | 1286.707 | / | 381.344 | |
= | 3.37413726 |
Current Ratio (Last Year: Mar22) | = | Total Current Assets | / | Total Current Liabilities |
= | 1208.045 | / | 306.687 | |
= | 3.939016 |
Teladoc Health's current ratio of this year was 3.37413726. Teladoc Health's current ratio of last year was 3.939016.
==> Last year's current ratio is higher ==> Score 0.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
Teladoc Health's number of shares in issue this year was 162.923. Teladoc Health's number of shares in issue last year was 160.532.
==> There is larger number of shares in issue this year. ==> Score 0.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
Gross Margin (This Year: TTM) | = | Gross Profit | / | Revenue |
= | 1723.665 | / | 2470.734 | |
= | 0.69763277 |
Gross Margin (Last Year: TTM) | = | Gross Profit | / | Revenue |
= | 1453.058 | / | 2144.382 | |
= | 0.67761154 |
Teladoc Health's gross margin of this year was 0.69763277. Teladoc Health's gross margin of last year was 0.67761154.
==> This year's gross margin is higher. ==> Score 1.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
Asset Turnover (This Year) | = | Revenue | / | Total Assets at the Beginning of This Year (Mar22) |
= | 2470.734 | / | 11092.337 | |
= | 0.22274242 |
Asset Turnover (Last Year) | = | Revenue | / | Total Assets at the Beginning of Last Year (Mar21) |
= | 2144.382 | / | 17582.358 | |
= | 0.12196214 |
Teladoc Health's asset turnover of this year was 0.22274242. Teladoc Health's asset turnover of last year was 0.12196214.
==> This year's asset turnover is higher. ==> Score 1.
Evaluation
Piotroski F-Score | = | Que. 1 | + | Que. 2 | + | Que. 3 | + | Que. 4 | + | Que. 5 | + | Que. 6 | + | Que. 7 | + | Que. 8 | + | Que. 9 |
= | 0 | + | 1 | + | 0 | + | 1 | + | 0 | + | 0 | + | 0 | + | 1 | + | 1 | |
= | 4 |
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Teladoc Health has an F-score of 4 indicating the company's financial situation is typical for a stable company.
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
Thank you for viewing the detailed overview of Teladoc Health's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.
Laizer Kornwasser | officer: PRESIDENT, ENTERPRISE GROWTH | 100 PARSONS POND DRIVE, FRANKLIN LAKES NJ 07417 |
Michael Willem Waters | officer: CHIEF OPERATING OFFICER | 2 MANHATTANVILLE ROAD, SUITE 203, PURCHASE NY 10577 |
Vidya Raman-tangella | officer: Chief Medical Officer | 2 MANHATTANVILLE ROAD, SUITE 203, PURCHASE NY 10577 |
Claus Torp Jensen | officer: Chief Innovation Officer | 2 MANHATTANVILLE ROAD, SUITE 203, PURCHASE NY 10577 |
Richard J Napolitano | officer: Chief Accounting Officer | MSCI INC., 7 WORLD TRADE CENTER, 250 GREENWICH STREET, 49TH FLOOR, NEW YORK NY 10007 |
Christopher Bischoff | director | C/O TELADOC HEALTH, INC., 2 MANHATTANVILLE ROAD, SUITE 203, PURCHASE NY 10577 |
Hemant Taneja | director | 14120 MIRANDA ROAD, LOS ALTOS HILLS CA 94022 |
Sandra L Fenwick | director | C/O TELADOC HEALTH, INC., 2 MANHATTANVILLE ROAD, SUITE 203, PURCHASE NY 10577 |
Karen L Daniel | director | 2801 80TH STREET, KENOSHA WI 53141 |
Yulun Wang | officer: Head of Research & Development | 130 B CREMONA DR, GOLETA CA 93117 |
Glen Tullman | director | C/O LIVONGO HEALTH, INC., 150 WEST EVELYN AVENUE, SUITE 150, MOUNTAIN VIEW CA 94041 |
Daniel Trencher | officer: SVP Corporate Strategy | 2 MANHATTANVILLE ROAD, SUITE 203, PURCHASE NY 10577 |
Arnnon Geshuri | officer: Chief Human Resources Officer | 2 MANHATTANVILLE ROAD, SUITE 203, PURCHASE NY 10577 |
Christopher Caridi | officer: Chief Accounting Officer | C/O 111 RIVER STREET, HOBOKEN NJ 07030 |
Catherine Jacobson | director | C/O TELADOC, INC., 2 MANHATTANVILLE ROAD, SUITE 203, PURCHASE NY 10577 |
From GuruFocus
By PRNewswire 01-07-2023
By PRNewswire 08-04-2022
By PRNewswire 08-03-2022
By Business Wire 08-03-2022
By Stock market mentor 01-05-2023
By PurpleRose 08-01-2022
By Value_Insider 10-24-2022
By PurpleRose 08-02-2022
Other Sources
By CNBC 2023-01-21
By Yahoo Finance 2023-01-10
By Zacks 2023-01-19
By Zacks 2023-01-25
By CNBC 2023-01-17
By Yahoo Finance 2023-01-12
By Yahoo Finance 2023-01-13
By Yahoo Finance 2023-01-18
By tipranks.com 2023-01-19
By Reuters 2023-01-18
By Yahoo Finance 2023-01-11
By Yahoo Finance 2023-01-23
By Yahoo Finance 2023-01-19
By Zacks 2023-01-19
By Yahoo Finance 2023-01-18